Clinical Trial Update: Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating incretin-based therapy for cardiovascular risk reduction and diabetes remission, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Cerebrovascular Disease
• Diabetes Mellitus

Snippet

Sponsor: China-Japan Friendship Hospital | Conditions: Diabetes Mellitus, Cardiovascular Diseases | Phase 4 | Status: ENROLLING_BY_INVITATION